menu search

AMYT / Amryt Pharma (AMYT) CEO Dr. Joe Wiley on Q4 2021 Results - Earnings Call Transcript

Amryt Pharma (AMYT) CEO Dr. Joe Wiley on Q4 2021 Results - Earnings Call Transcript
Amryt Pharma (AMYT) CEO Dr. Joe Wiley on Q4 2021 Results - Earnings Call Transcript Read More
Posted: Mar 9 2022, 13:37
Author Name: Seeking Alpha
Views: 102179

AMYT News  

Amryt Pharma: Final Chance To Pick Up An Attractive CVR

By Seeking Alpha
April 11, 2023

Amryt Pharma: Final Chance To Pick Up An Attractive CVR

Amryt Pharma is being acquired at $14.50 per share and a contingent value right and is trading at $14.69. The contingent value right consists of 2 mil more_horizontal

Why Shares of Amryt Pharma Jumped This Week

By The Motley Fool
January 12, 2023

Why Shares of Amryt Pharma Jumped This Week

A takeover bid by an Italian pharmaceutical and healthcare company boosted Amryt's shares. more_horizontal

Acquisition Of Amryt Pharma: How To Profit From Orphan Drugs Developers

By Seeking Alpha
January 12, 2023

Acquisition Of Amryt Pharma: How To Profit From Orphan Drugs Developers

Amryt Pharma plc will be acquired by Chiesi Farmaceutici S.p.A. Amryt Pharma is valued at $1.25 billion plus $225 million upon achievement of certain more_horizontal

Amryt Pharma PLC (AMYT) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 5, 2022

Amryt Pharma PLC (AMYT) Q3 2022 Earnings Call Transcript

Amryt Pharma PLC (NASDAQ:AMYT ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Con more_horizontal

Amryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
August 6, 2022

Amryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call Transcript

Amryt Pharma plc (NASDAQ:AMYT ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Contr more_horizontal

Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome

By Zacks Investment Research
July 14, 2022

Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome

The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading. more_horizontal

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022

By GlobeNewsWire
June 8, 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 more_horizontal

Amryt Pharma PLC (AMYT) CEO Joseph Wiley on Q1 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 8, 2022

Amryt Pharma PLC (AMYT) CEO Joseph Wiley on Q1 2022 Results - Earnings Call Transcript

Amryt Pharma PLC (NASDAQ:AMYT ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Controll more_horizontal


Search within

Pages Search Results: